Publications

  1. Hampel PJ, Rabe KG, Call KG, Ding TG, Leis W, Kenderian JF, Muchtar SS, Wang E, Koehler Y, Parrondo AB, Schwager R, Shi SM, Braggio M, Slager E, Kay SL, Parikh NE. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. Br J Haematol. 2022 Oct; 199 (2):239-244 Epub 2022 July 16
    View PubMed
  2. Hampel PJ, Rabe KG, Call KG, Ding TG, Leis W, Chanan-Khan JF, Kenderian AA, Muchtar SS, Wang E, Ailawadhi Y, Koehler S, Parrondo AB, Schwager R, Sher SM, Hanson T, Shi CA, Van Dyke M, Braggio DL, Slager E, Kay SL, Parikh NE. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer J. 2022 Sep 1; 12 (9):124 Epub 2022 Sept 01
    View PubMed
  3. Perales MA, Anderson LD Jr, Jain T, Kenderian SS, Oluwole OO, Shah GL, Svoboda J, Hamadani M. Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther 2022 Sep; 28 (9):546-559 Epub 2022 June 26
    View PubMed
  4. Alkhateeb HB, Mohty R, Greipp P, Bansal R, Hathcock M, Rosenthal A, Murthy H, Kharfan-Dabaja M, Bisneto Villasboas JC, Bennani N, Ansell SM, Patnaik MM, Litzow MR, He R, Chen D, Al-Kali A, Kenderian SS, Lin Y, Shah MV. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma. Blood Cancer J 2022 Jul 26; 12 (7):113 Epub 2022 July 26
    View PubMed
  5. Soof CM, Spektor TM, Parikh SA, Slager SL, Rabe KG, Call KG, Kenderian TG, Ding SS, Muchtar W, Ghermezi E, Kay M, Berenson NE. Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. Exp Hematol. 2022 Jul; 111:32-40 Epub 2022 May 05
    View PubMed
  6. Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Nevala WK, Walters DK, Parikh SA, Lin Y, Jelinek DF, Kay NE, Bergsagel PL, Kenderian SS. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood. 2022 Jun 30; 139 (26):3708-3721
    View PubMed
  7. Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Mol Ther Oncolytics. 2022 Jun 16; 25:69-77 Epub 2022 Mar 19
    View PubMed
  8. Cox MJ, Manriquez Roman C, Tapper EE, Siegler EL, Chappell D, Durrant C, Ahmed O, Sinha S, Mwangi R, Scott NS, Hefazi M, Schick KJ, Horvei P, Ruff MW, Can I, Adada M, Bezerra E, Kankeu Fonkoua LA, Parikh SA, Kay NE, Sakemura R, Kenderian SS. GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia. 2022 Jun; 36 (6):1635-1645 Epub 2022 Apr 19
    View PubMed
  9. Wang H, Tian S, Zhao Q, Blumenschein W, Yearley JH, Secreto CR, Sinha S, Call TG, Wang Y, Parikh SA, Kenderian SS, He R, Leis JF, Shi M, Van Dyke DL, Kay NE, Slager SL, Braggio E, Yan H, Ding W. Differential transcriptomic profiling in ibrutinib-naive versus ibrutinib-resistant Richter syndrome. Hematol Oncol 2022 Apr; 40 (2):302-306 Epub 2021 Dec 03
    View PubMed
  10. Can I, Cox MJ, Siegler EL, Sakemura R, Kenderian SS. Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned. Exp Hematol. 2022 Apr; 108:1-7 Epub 2022 Feb 10
    View PubMed
  11. Sakemura R, Cox MJ, Bansal A, Roman CM, Hefazi M, Vernon CJ, Glynn DL, Pandey MK, DeGrado TR, Siegler EL, Kenderian SS. Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography. J Vis Exp. 2022 Feb 17; (180)
    View PubMed
  12. King RL, Gupta A, Kurtin PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Leis JF, Wang Y, Schwager SM, Slager SL, Kay NE, Koehler A, Ansell SM, Inwards DJ, Habermann TM, Shi M, Hanson CA, Howard MT, Parikh SA. Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter? Blood Cancer J. 2022 Jan 28; 12 (1):18
    View PubMed
  13. Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding KG, Call W, Leis TG, Kenderian JF, Hayman SS, Wang SR, Hampel Y, Holets PJ, Darby MA, Slager HC, Kay SL, Miao NE, Canniff C, Whitaker J, Levin JA, Schmid MJ, Kennedy DS, Weinberg RB, Parikh A. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol. 2022 Jan 1; 97 (1):90-98 Epub 2021 Nov 05
    View PubMed
  14. Shakshouk H, Tkaczyk ER, Cowen EW, El-Azhary RA, Hashmi SK, Kenderian SJ, Lehman JS. Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review. Transplant Cell Ther. 2021 Sep; 27 (9):738-746 Epub 2021 June 06
    View PubMed
  15. Sakemura R, Bansal A, Siegler EL, Hefazi M, Yang N, Khadka RH, Newsom AN, Hansen MJ, Cox MJ, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Nevala WK, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Horvei P, Ruff MW, Parikh SA, Pandey MK, DeGrado TR, Suksanpaisan L, Kay NE, Peng KW, Russell SJ, Kenderian SS. Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. Cancer Immunol Res. 2021 Sep; 9 (9):1035-1046 Epub 2021 July 08
    View PubMed
  16. Sakemura R, Cox MJ, Hefazi M, Siegler EL, Kenderian SS. Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. Leuk Lymphoma. 2021 Sep; 62 (9):2052-2063 Epub 2021 Mar 08
    View PubMed
  17. Wang Y, Achenbach SJ, Rabe KG, Shanafelt KG, Call TD, Ding TG, Kenderian W, Muchtar SS, Leis E, Koehler JF, Schwager AB, Cerhan SM, Slager JR, Kay SL, Parikh NE. Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. Blood Cancer J 2021 Aug 5; 11 (8):140 Epub 2021 Aug 05
    View PubMed
  18. Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Leis JF, Kenderian SS, Muchtar E, Wang Y, Koehler AB, Schwager SM, Lesnick CE, Kleinstern G, Van Dyke D, Hanson CA, Braggio E, Slager SL, Shanafelt TD. The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood. 2021 Jul 15; 138 (2):149-159
    View PubMed
  19. Audil HY, Hampel PJ, Van Dyke DL, Achenbach SJ, Rabe KG, Smoley SA, Call TG, Ding W, Shi M, Hanson CA, Wang Y, Muchtar E, Koehler AB, Schwager SM, Leis JF, Braggio E, Slager SL, Kay NE, Kenderian SS, Parikh SA. The prognostic significance of del6q23 in chronic lymphocytic leukemia. Am J Hematol 2021 Jun 1; 96 (6):E203-E206 Epub 2021 Apr 07
    View PubMed
  20. Wang Y, Sinha S, Wellik LE, Secreto CR, Rech KL, Call TG, Parikh SA, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Van Dyke DL, Leis JF, Slager SL, Dong H, Kay NE, He R, Ding W. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. Blood Cancer J. 2021 May 10; 11 (5):86
    View PubMed
  21. Cox MJ, Lucien F, Sakemura R, Boysen JC, Kim Y, Horvei P, Manriquez Roman C, Hansen MJ, Tapper EE, Siegler EL, Forsman C, Crotts SB, Schick KJ, Hefazi M, Ruff MW, Can I, Adada M, Bezerra E, Kankeu Fonkoua LA, Nevala WK, Braggio E, Ding W, Parikh SA, Kay NE, Kenderian SS. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. Mol Ther. 2021 Apr 07; 29(4):1529-1540. Epub 2021 Jan 01.
    View PubMed
  22. Sakemura R, Can I, Siegler EL, Kenderian SS. In vivo CART cell imaging: Paving the way for success in CART cell therapy. Mol Ther Oncolytics. 2021 Mar 26; 20:625-633 Epub 2021 Mar 05
    View PubMed
  23. Hampel PJ, Parikh SA, Call TG, Shah MV, Bennani NN, Al-Kali A, Rabe KG, Wang Y, Muchtar E, Leis JF, Kenderian SS, Koehler AB, Schwager SM, Slager SL, Kay NE, Hanson CA, Van Dyke DL, Shi M, Ding W. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer J 2021 Mar 2; 11 (3):47 Epub 2021 Mar 02
    View PubMed
  24. Manriquez-Roman C, Siegler EL, Kenderian SS. CRISPR Takes the Front Seat in CART-Cell Development. BioDrugs. 2021 Mar; 35 (2):113-124 Epub 2021 Feb 27
    View PubMed
  25. Archibald WJ, Rabe KG, Kabat BF, Herrmann J, Ding W, Kay NE, Kenderian SS, Muchtar E, Leis JF, Wang Y, Chanan-Khan AA, Schwager SM, Koehler AB, Fonder AL, Slager SL, Shanafelt TD, Call TG, Parikh SA. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. Ann Hematol. 2021 Jan; 100 (1):143-155 Epub 2020 June 01
    View PubMed
  26. Aboulnasr F, Krogman A, Graham RP, Cummins NW, Misra A, Garcia-Rivera E, Anderson JR, Natesampillai S, Kogan N, Aravamudan M, Nie Z, Chung TDY, Buick R, Feldman AL, King RL, Novak AJ, Ansell SM, Kenderian S, Badley AD. Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. Clin Cancer Res. 2020 Nov 1; 26 (21):5759-5771 Epub 2020 July 15
    View PubMed
  27. Hampel PJ, Call TG, Rabe KG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. Oncologist. 2020 Nov; 25 (11):974-980 Epub 2020 Sept 20
    View PubMed
  28. Wang Y, Rabe KG, Bold MS, Shi M, Hanson CA, Schwager SM, Call TG, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Fonder AL, Chanan-Khan AA, Van Dyke DL, Slager SL, Kay NE, Ding W, Leis JF, Parikh SA. The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica 2020 Nov 1; 105 (11):2675-2678 Epub 2020 Nov 01
    View PubMed
  29. Temesgen Z, Assi M, Shweta FNU, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD, Orenstein R, Vargas HE, Palraj R, Dababneh AS, Chappell G, Chappell D, Ahmed O, Sakemura R, Durrant C, Kenderian SS, Badley AD. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 Nov; 95 (11):2382-2394 Epub 2020 Sept 03
    View PubMed
  30. Koehler AB, Leung N, Call TG, Rabe KG, Achenbach SJ, Ding W, Kenderian SS, Leis JF, Wang Y, Muchtar E, Hayman SR, Hampel PJ, Finnes HD, Schwager SM, Slager SL, Kay NE, Parikh SA. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. Leuk Lymphoma. 2020 Oct; 61 (10):2383-2388 Epub 2020 May 25
    View PubMed
  31. Mohty M, Dulery R, Gauthier J, Malard F, Brissot E, Aljurf M, Bazarbachi A, Chabanon C, Kharfan-Dabaja MA, Savani BN, Huang H, Kenderian SS, Perales MA, Yakoub-Agha I, Nagler A. CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplant. 2020 Aug; 55 (8):1525-1532 Epub 2020 Apr 18
    View PubMed
  32. Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, Yashiro-Ohtani Y, Kenderian SS, Kim MY, O'Connor RS, Wallace SR, Kozlowski MS, Marchione DM, Shestov M, Garcia BA, June CH, Gill S. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020 Aug; 38 (8):947-953 Epub 2020 Mar 23
    View PubMed
  33. Heybeli C, Sridharan M, Alkhateeb HB, Villasboas Bisneto JC, Buadi FK, Chen D, Dingli D, Dispenzieri A, Gertz MA, Go RS, Hashmi SK, Hayman SR, Hogan WJ, Inwards DJ, Kenderian SS, Kumar SK, Litzow MR, Porrata LF, Lacy MQ, Micallef IN, Patnaik MM, Shah MV, Leung N. Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2020 Jul 2 Epub 2020 July 02
    View PubMed
  34. Parikh SA, Achenbach SJ, Call TG, Rabe KG, Ding W, Leis JF, Kenderian SS, Chanan-Khan AA, Koehler AB, Schwager SM, Muchtar E, Fonder AL, McCullough KB, Nedved AN, Smith MD, Slager SL, Kay NE, Finnes HD, Shanafelt TD. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med. 2020 May; 9 (10):3390-3399 Epub 2020 Mar 18
    View PubMed
  35. Sterner RM, Hedin KE, Hayden RE, Nowakowski GS, Wyles SP, Greenberg-Worisek AJ, Terzic A, Kenderian SS. A Graduate-Level Interdisciplinary Curriculum in CAR-T Cell Therapy. Mayo Clin Proc Innov Qual Outcomes. 2020 Apr; 4 (2):203-210 Epub 2020 Mar 16
    View PubMed
  36. Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, Kay NE, Muchtar E, Van Dyke DL, Koehler AB, Schwager SM, Slager SL, Parikh SA, Ding W. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020 Mar; 105 (3):765-773 Epub 2019 June 13
    View PubMed
  37. Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Rabe KG, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. Am J Hematol 2020 Mar; 95 (3):E57-E60 Epub 2019 Dec 13
    View PubMed
  38. Siegler EL, Kenderian SS. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Front Immunol. 2020; 11:1973 Epub 2020 Aug 28
    View PubMed
  39. Sterner RM, Kenderian SS. Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. Curr Opin Hematol. 2020 Jan; 27 (1):41-48
    View PubMed
  40. Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, Chabannon C, Kharfan-Dabaja MA, Savani BN, Huang H, Kenderian S, Nagler A, Perales MA. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia. 2019 Dec; 33 (12):2767-2778 Epub 2019 Nov 05
    View PubMed
  41. Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplant. 2019 Nov; 54 (11):1868-1880 Epub 2019 May 15
    View PubMed
  42. Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019 Nov; 60 (11):2712-2719 Epub 2019 Apr 24
    View PubMed
  43. Sterner RM, Cox MJ, Sakemura R, Kenderian SS. Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells. J Vis Exp. 2019 Jul 22; (149).
    View PubMed
  44. Khadka RH, Sakemura R, Kenderian SS, Johnson AJ. Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy. 2019 Jul; 11 (10):851-857 Epub 2019 June 04
    View PubMed
  45. Lehman JS, Dasari S, Damodaran SS, El-Azhary RA, Gibson LE, Hashmi SK, Hogan WJ, Kenderian SJ, Patnaik MS, Litzow MR, Lazarus HM, Meves A. Differential expression of interferon-induced genes and other tissue-based biomarkers in acute graft-versus-host disease vs. lupus erythematosus in skin. Clin Exp Dermatol. 2019 Jun; 44 (4):e81-e88 Epub 2018 Oct 02
    View PubMed
  46. Mochel JP, Ekker SC, Johannes CM, Jergens AE, Allenspach K, Bourgois-Mochel A, Knouse M, Benzekry S, Wierson W, LeBlanc AK, Kenderian SS. CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies. AAPS J. 2019 Apr 8; 21 (3):50 Epub 2019 Apr 08
    View PubMed
  47. Fang H, Reichard KK, Rabe KG, Hanson CA, Call TG, Ding W, Kenderian SS, Muchtar E, Schwager SM, Leis JF, Chanan-Khan AA, Slager SL, Braggio E, Smoley SA, Kay NE, Shanafelt TD, Van Dyke DL, Parikh SA. IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. Am J Hematol. 2019 Mar; 94 (3):338-345 Epub 2019 Jan 08
    View PubMed
  48. Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14; 133 (7):697-709 Epub 2018 Nov 21
    View PubMed
  49. Vera-Aguilera J, Duma N, Gast K, Alkhateeb H, Tande A, Leung N, Hogan WJ, Kenderian SJ. Hemolytic Uremic Syndrome Associated With Escherichia coli O157 Infection in an Allogenic Stem Cell Transplant Recipient. Mayo Clin Proc Innov Qual Outcomes. 2018 Dec; 2 (4):387-391 Epub 2018 Sept 15
    View PubMed
  50. Rodriguez-Cartagena LG, Bowles BS, Kurani SS, Windebank AJ, Kenderian SS, Greenberg-Worisek AJ. Chimeric Antigen Receptor T-Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside. Clin Transl Sci. 2018 Nov; 11 (6):537-539 Epub 2018 Sept 22
    View PubMed
  51. Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, Bowen D, Boysen J, Schwager SM, Leis JF, Chanan-Khan AA, Muchtar E, Hanson CA, Slager SL, Kay NE, Chaffee KG, Shanafelt TD, Parikh SA. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. Br J Haematol. 2018 Nov; 183 (3):421-427 Epub 2018 Aug 16
    View PubMed
  52. Perez Botero J, Ho TP, Hogan WJ, Kenderian S, Gangat N, Tefferi A, Abraham RS, Nguyen P, Oliveira JL, He R, Chen D, Viswanatha D, Rodriguez V, Khan SP, Patnaik MM. Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. Br J Haematol. 2018 Jul; 182 (1):141-145 Epub 2017 May 09
    View PubMed
  53. Parikh SA, Chaffee KG, Larson MC, Hampel PJ, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Conte MJ, Bowen D, Schwager SM, Slager SL, Hanson CA, Kay NE, Shanafelt TD. Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. Haematologica 2018 Jun; 103 (6):e237-e240 Epub 2018 Feb 01
    View PubMed
  54. Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 2018 May 31; 173 (6):1439-1453.e19
    View PubMed
  55. Ruella M, Kenderian SS. Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. BioDrugs. 2017 Dec; 31 (6):473-481
    View PubMed
  56. Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA. Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. Am J Hematol. 2017 Dec; 92 (12):1362-1369 Epub 2017 Oct 19
    View PubMed
  57. Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S. Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discov. 2017 Oct; 7 (10):1154-1167 Epub 2017 June 02
    View PubMed
  58. Finnes HD, Chaffee KG, Call TG, Ding W, Kenderian SS, Bowen DA, Conte M, McCullough KB, Merten JA, Bartoo GT, Smith MD, Leis J, Chanan-Khan A, Schwager SM, Slager SL, Kay NE, Shanafelt TD, Parikh SA. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma. 2017 Jun; 58 (6):1376-1383 Epub 2016 Nov 08
    View PubMed
  59. Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood. 2017 Apr 27; 129 (17):2395-2407 Epub 2017 Feb 28
    View PubMed
  60. Kenderian SS, Porter DL, Gill S. Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. Biol Blood Marrow Transplant. 2017 Feb; 23 (2):235-246 Epub 2016 Sept 13
    View PubMed
  61. Tabibian JH, Kenderian SS. The Microbiome and Immune Regulation After Transplantation. Transplantation. 2017 Jan; 101 (1):56-62
    View PubMed
  62. Kenderian SS, June CH, Gill S. Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia. Methods Mol Biol. 2017; 1633:267-276
    View PubMed
  63. Dias A, Kenderian SJ, Westin GF, Litzow MR. Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2016 Aug; 11 (4):253-64
    View PubMed
  64. Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clin Cancer Res. 2016 Jun 1; 22 (11):2684-96 Epub 2016 Jan 27
    View PubMed
  65. Kenderian SS, Habermann TM, Macon WR, Ristow KM, Ansell SM, Colgan JP, Johnston PB, Inwards DJ, Markovic SN, Micallef IN, Thompson CA, Porrata LF, Martenson JA, Witzig TE, Nowakowski GS. Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. Blood. 2016 Apr 21; 127 (16):1960-6 Epub 2016 Feb 02
    View PubMed
  66. Eskandar A, Ahmed A, Daughtey M, Kenderian S, Mahdi F, Khan A. Racial and sex differences in presentation and outcomes of small cell lung cancer in the United States: 1973 to 2010. Chest 2015 Apr; 147 (4):e164-e165
    View PubMed
  67. Rosado FG, Oliveira JL, Sohani AR, Schroyens W, Sykes DB, Kenderian SS, Lacy MQ, Kyle RA, Hoyer JD. Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist. Mod Pathol. 2015 Mar; 28 (3):367-72 Epub 2014 Sept 12
    View PubMed
  68. Kenderian SS, Litzow M. Acute Lymphoblastic Leukemia in Adolescents and Young Adults: From Genomics to the Clinic Clinical Oncology in Adolescents and Young Adults .2013;2013:(3)49-62.
  69. Sirop SJ, Ingle JN, Goetz MP. Clinical use of selective estrogen receptor modulators and aromatase inhibitors in prevention and adjuvant treatment of bresat cancer. Translational Endocrincology and Metabolism, The Endocrine Society. 2012; 3(1):139-167.
  70. Soni M, Wiese D, Korant A, Sirop S, Chakravarty B, Gayar A, Bilchik A, Beutler T, Ratz D, Saha S. Comparison of nodal positivity between SLNM vs conventional surgery in colon cancer patients with <12 and >/=12 lymph nodes harvested. Am J Surg. 2011 Aug; 202: (2)207-13.
    View PubMed
  71. Sirop S, Kanaan M, Korant A, Wiese D, Eilender D, Nagpal S, Arora M, Singh T, Saha S. Detection and prognostic impact of micrometastasis in colorectal cancer. J Surg Oncol. 2011 May 1; 103: (6)534-7.
    View PubMed
  72. Saha S, Sirop S, Korant A, Kanaan M, Shekher R, Strahle D, Hicks M, Hicks R, Lawrence L, Wiese D. Nodal positivity in breast cancer correlated with the number of lesions detected by magnetic resonance imaging versus mammogram. Am J Surg. 2011 Mar; 201: (3)390-4; discussion 394-5.
    View PubMed
  73. Sirop SJ, Haluska P. Insulin-like growth factor pathway-targeted therapy in breast cancer. Current Breast Cancer Reports. 2011; 3(1):6-14.
  74. Wiese D, Sirop S, Yestrepsky B, Ghanem M, Bassily N, Ng P, Liu W, Quiachon E, Ahsan A, Badin J, Saha S. Ultrastaging of sentinel lymph nodes (SLNs) vs. non-SLNs in colorectal cancer--do we need both? Am J Surg. 2010 Mar; 199: (3)354-8; discussion 358.
    View PubMed
  75. Soni M, Saha S, Korant A, Fritz P, Chakravarty B, Sirop S, Gayar A, Iddings D, Wiese D. A prospective trial comparing 1% lymphazurin vs 1% methylene blue in sentinel lymph node mapping of gastrointestinal tumors. Ann Surg Oncol. 2009 Aug; 16: (8)2224-30.
    View PubMed
  76. Cahill RA, Bembenek A, Sirop S, Waterhouse DF, Schneider W, Leroy J, Wiese D, Beutler T, Bilchik A, Saha S, Schlag PM. Sentinel node biopsy for the individualization of surgical strategy for cure of early-stage colon cancer. Ann Surg Oncol. 2009 Aug; 16: (8)2170-80.
    View PubMed
  77. Wiese D, Saha S, Yestrepsky B, Korant A, Sirop S. A prospective study of false-positive diagnosis of micrometastatic cells in the sentinel lymph nodes in colorectal cancer. Ann Surg Oncol. 2009 Aug; 16: (8)2166-9.
    View PubMed